0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Amyotrophic lateral sclerosis (ALS) -Epidemiology Forecast to 2028
Published Date: February 2019
|
Report Code: DELV-Epid-46
Home | Market Reports | Health | Health Conditions | Neurological Conditions
Amyotrophic lateral sclerosis  Epidemiology Forecast to 2028

Amyotrophic lateral sclerosis (ALS) -Epidemiology Forecast to 2028

Code: DELV-Epid-46
Report
February 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Amyotrophic lateral sclerosis (ALS) - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Amyotrophic lateral sclerosis (ALS) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Amyotrophic lateral sclerosis (ALS) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Amyotrophic lateral sclerosis (ALS) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Amyotrophic lateral sclerosis (ALS) outlook. It also includes the explanation of changing trends of epidemiology outlining the Amyotrophic lateral sclerosis (ALS) scenario.

Amyotrophic lateral sclerosis (ALS) Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Amyotrophic lateral sclerosis (ALS) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Amyotrophic lateral sclerosis (ALS) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Amyotrophic lateral sclerosis (ALS) Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Amyotrophic lateral sclerosis (ALS)

Key assessments
• Patient Segmentation in Amyotrophic lateral sclerosis (ALS)
• Amyotrophic lateral sclerosis (ALS) Risk & Burden
• Factors driving growth in a specific Amyotrophic lateral sclerosis (ALS) patient population

  1. Report Introduction
    2. Amyotrophic lateral sclerosis (ALS) Epidemiology Overview at a Glance
    2.1. Patient Share Distribution of Amyotrophic lateral sclerosis (ALS) in 2016
    2.2. Patient Share Distribution of Amyotrophic lateral sclerosis (ALS) in 2028
    3. Disease Background and Overview: Amyotrophic lateral sclerosis (ALS)
    3.1. Introduction
    3.2. Symptoms
    3.3. Etiology
    3.4. Risk Factors
    3.5. Pathophysiology
    3.6. Diagnosis
    3.7. Treatment
    4. Epidemiology and Patient Population
    4.1. Key Findings
    4.2. Total Prevalent/ Incident Patient Population of Amyotrophic lateral sclerosis (ALS) in 7MM
    4.3. Total Prevalent/ Incident Patient Population of Amyotrophic lateral sclerosis (ALS) in 7MM – By Countries
    5. Epidemiology of Amyotrophic lateral sclerosis (ALS) by Countries
    5.1. United States
    5.1.1. Assumptions and Rationale
    5.1.2. Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS)
    5.1.3. Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) *
    5.1.4. Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS)*
    5.1.5. Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS)
    5.2. EU5
    5.3. Assumptions and Rationale
    5.4. Germany
    5.4.1. Assumptions and Rationale
    5.4.2. Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS)
    5.4.3. Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS)*
    5.4.4. Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS)*
    5.4.5. Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS)
    5.5. France
    5.5.1. Assumptions and Rationale
    5.5.2. Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS)
    5.5.3. Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS)*
    5.5.4. Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS)*
    5.5.5. Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS)
    5.6. Italy
    5.6.1. Assumptions and Rationale
    5.6.2. Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS)
    5.6.3. Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS)*
    5.6.4. Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS)*
    5.6.5. Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS)
    5.7. Spain
    5.7.1. Assumptions and Rationale
    5.7.2. Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS)
    5.7.3. Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS)*
    5.7.4. Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS)*
    5.7.5. Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS)
    5.8. United Kingdom
    5.8.1. Assumptions and Rationale
    5.8.2. Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS)
    5.8.3. Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS)*
    5.8.4. Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS)*
    5.8.5. Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS)
    5.9. Japan
    5.9.1. Assumptions and Rationale
    5.9.2. Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS)
    5.9.3. Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS)*
    5.9.4. Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS)*
    5.9.5. Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS)
    6. Unmet Needs of the Amyotrophic lateral sclerosis (ALS)
    7. Appendix
    8. Report Methodology
    8.1. Sources
    9. DelveInsight Capabilities
    10. Disclaimer
    11. About DelveInsight
    *Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028) *
Table 14: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028)


List of Figures

Figure 1: Total Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in Japan (2016-2028)

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Strategic Venue Partners